Market Place
Sourcing Support
Medison Announces Public Formulary Listing of QINLOCK in Canadian Provinces
29 Sep 2023 //
PR NEWSWIRE
Deciphera Pharmaceuticals to Present Data from INTRIGUE Phase 3 Study of QINLOCK
25 May 2023 //
BUSINESSWIRE
New Therapy To Treat GIST Approved For New Zealand Patients
19 Jan 2023 //
PR NEWSWIRE
Deciphera Presents Phase 1 Single Agent Dose Escalation Data for DCC-3116
10 Sep 2022 //
BUSINESSWIRE
Deciphera Pharma Announces Publication of Phase 3 Clinical Study Results
10 Aug 2022 //
BUSINESS WIRE
Deciphera Presents Results from INTRIGUE Phase 3 Study at ASCO
24 Jan 2022 //
BUSINESSWIRE
Deciphera Announces Approval of QINLOCK in the United Kingdom
21 Dec 2021 //
BIOSPACE
Deciphera Announces Approval of QINLOCK in UK
21 Dec 2021 //
BUSINESSWIRE
Deciphera Pharmaceuticals` Qinlock (ripretinib) Receives Approval in Europe
23 Nov 2021 //
EMA
Deciphera Receives EC Approval of QINLOCK for Gastrointestinal Stromal Tumor
22 Nov 2021 //
BUSINESSWIRE
Deciphera Announces Approval of QINLOCK in Switzerland
12 Oct 2021 //
BUSINESSWIRE
Deciphera Announces Approval of QINLOCK® in Switzerland for the Treatment
12 Oct 2021 //
BUSINESSWIRE
Ripretinib Improves Survival in Patients With Advanced GIST: ESMO Congress
20 Sep 2021 //
FIRSTWORDPHARMA
Deciphera Announces Positive CHMP Opinion for QINLOCK®
17 Sep 2021 //
BUSINESSWIRE
Update on INVICTUS Trial Shows Improved Overall Median Survival Using Ripretinib
17 Sep 2021 //
FOXCHASE
Medison Pharma Enters Exclusive Distribution Agreement with Deciphera
06 Nov 2020 //
PRNEWSWIRE
Deciphera Presents Data from QINLOCK™ (Ripretinib) Program at the ESMO
18 Sep 2020 //
BIOSPACE
Deciphera Announces Publication of QINLOCK™ (ripretinib) Ph1 Study
17 Aug 2020 //
BUSINESSINSIDER
Zai Lab Announces NDA for Ripretinib Granted Priority Review by China’s NMPA
04 Aug 2020 //
GLOBENEWSWIRE
Deciphera Announces Presentation of Analysis of Crossover Ph3 Study of QINLOCK™
02 Jul 2020 //
BUSINESSWIRE
Deciphera Announces Health Canada’s Authorization of QINLOCK™ (ripretinib)
22 Jun 2020 //
BUSINESSWIRE
Deciphera Announces Publication of the INVICTUS Pivotal Ph3 Study of QINLOCK™
07 Jun 2020 //
BUSINESSWIRE
AmerisourceBergen Selected by Deciphera Pharmaceuticals to Support QINLOCK™
26 May 2020 //
BUSINESSWIRE
Deciphera wins early FDA nod for Qinlock in rare stomach cancer
19 May 2020 //
FIERCE PHARMA
PANTHERx® Rare Pharmacy Selected by Deciphera Pharma to Distribute QINLOCK™
18 May 2020 //
PRNEWSWIRE
Deciphera Pharmaceuticals Announces Submission of NDA TO FDA for Ripretinib
16 Dec 2019 //
BUSINESS WIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.